补肾活血复方对帕金森病轻度认知障碍的辅助治疗作用

Effects of Bushen-Huoxue compound adjuvant therapy on mild cognitive impairment in Parkinson＆#39;s disease

目的：探讨补肾活血复方对帕金森病（Parkinson’s disease，PD）轻度认知功能障碍（mild cognitive impairment，MCI）的辅助治疗作用，以及对PD-MCI患者血浆磷脂（phospholipids，PLs）含量的影响。方法收集2009年5月至2012年1月威海市立医院神经内科就诊PD-MCI患者39例，按照随机数字表法将患者随机分为对照组19例和治疗组20例，对照组采用常规药物治疗，治疗组在对照组治疗基础上加用补肾活血复方，60 ml/次，3次/d，30 d为1个疗程。分别于治疗前后12个月和18个月进行MoCA评测及PLs含量测定。结果治疗后12个月、18个月，治疗组MoCA评分[（19.86±2.58）分，（18.97±4.36）分]与对照组[（16.59±4.06）分，（14.99±3.72）分]比较，差异有统计学意义（t值分别为5.43、6.67，P＜0.05或0.01）；治疗后12个月、18个月，治疗组血浆PLs含量[（5.20±0.74）U、（5.09±0.94）U]较对照组[（6.77±1.01）U、（7.12±1.13）U]显著降低（t值分别为6.89、7.06，P＜0.01）。结论补肾活血复方辅助治疗可延缓PD-MCI患者认知功能下降速率，并能降低其血浆PLs含量，具有神经保护作用。

Objective To investigate whether Bushen-Huoxue compound adjuvant therapy can be effective on mild cognitive impairment in Parkinson＇s disease and the influence on plasma phospholipids（PLs） levels. Methods 87 PD patients were recruited and collected for the general information. The patients were evaluated by Unified Parkinson＇s Disease Rating Scale（UPDRS） Ⅲ and Montreal Cognitive Assessment（MoCA）. According to MoCA scores, patients with PD-MCI were divided into a Bushen-Huoxue compound treatment group and a control group（basic L-dopa or dopamine agonist）. Reevaluating cognitive function by MoCA and plasma phopholipids levels at posttreatment 12 month and 18 month. Plasma PLs was assayed by measuring its inorganic phosphorus after separation by chromatograph.Results 39 cases in 87 PD patients（44.8%）were with PD-MCI.After 12 months or 18 months treatment period, MoCA scores was significantly higher in Bushen-Huoxue compound treatment group than in controls（P〈0.05 or 0.01 respectively）. Plasma PLs levels were significantly decreased in Bushen-Huoxue compound treatment group than in controls（P〈0.01 or 0.01 respectively）. Conclusions Bushen-Huoxue compound could be effective in the adjuvant treatment of PD-MCI, and could delay cognitive rate of decline in patients with PD. Meanwhile, Bushen-Huoxue compound could significantly decrease plasma PLs levels in PD-MCI. The evidence from present study suggested that Bushen-Huoxue compound have neuroprotective effects on patients with PD-MCI.